UNGER, THOMAS,KINTSCHER, ULRICH,KAUSCHKE, STEFAN,MARK, MICHAEL
申请号：
EP10177920.5
公开号：
EP2263670B1
申请日:
2004.07.24
申请国别(地区):
EP
年份:
2015
代理人:
摘要：
Die Erfindung betrifft die Verwendung von Angiotensin II Rezeptor Antagonisten zur Behandlung von Personen, bei denen Diabetes Mellitus Typ 2 diagnostiziert wurde oder Verdacht auf Prädiabetes besteht, zur Prävention von Diabetes oder zur Behandlung des Metabolischen Syndroms und der Insulin Resistenz in Patienten mit normalem Blutdruck.Angiotensin II receptor antagonist is used to prepare a medicament for treating people for whom type 2 diabetes has been diagnosed or prediabetes is suspected, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure. An independent claim is also included for a composition comprising telmisartan in combination with: amlodipine or nifedipine eplerenone or spironolactone simvastatin or atorvastatin rosiglitazone, pioglitazone, repaglinide or metformin dipyridamol or clopidogrel, optionally in combination with aspirin an aldosterone antagonist a HMG-CoA reductase inhibitor a dipeptidyl peptidase 4 inhibitor a sulfonylurea or a thrombocyte aggregation inhibitor. ACTIVITY : Antidiabetic. MECHANISM OF ACTION : Angiotensin II Receptor Antagonist Peroxisomal Proliferator Activated Receptor Gamma (PPARgamma) Activator. PC12W cells overexpressing PPARgamma 2 and its heterodimer partner RXRalpha were treated with telmisartan (10 MicroM). PPARgamma activity was increased by a factor of 1.9.
